Investors & Media
Corporate Profile
We are a clinical stage chemoprotection oncology company focused on developing medicines to make chemotherapy safer and thereby more effective to save more patients’ lives.
ALRN-6924, our first-in-class MDM2/MDMX dual inhibitor, is designed to activate p53, which in turn upregulates p21, a known inhibitor of the cell replication cycle. ALRN-6924 is the only reported chemoprotective agent in clinical development to employ a biomarker strategy, focusing exclusively on treating patients with p53-mutated cancers.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
OUR MISSION:To develop a targeted drug that prevents chemotherapy-induced side effects to help patients fight cancer more effectively with a better quality of life
OUR VISION:To bring chemoprotection to all patients with p53-mutated cancer regardless of the type of cancer or chemotherapy